CB-11 by Cellebrain for Glioblastoma Multiforme (GBM): Likelihood of Approval

Ipsen and Gen­fit re­vealed on Mon­day that their pri­ma­ry bil­iary cholan­gi­tis (PBC) drug can­di­date has met ad­di­tion­al end­points in a reg­is­tra­tional tri­al, adding fu­el to

“I think primarily this is a story of discovery,” said neurologist and multiple sclerosis (MS) researcher Stephen Hauser, MD, of the University of California San